Agios Pharmaceuticals, Inc. (0HB0.L)
0HB0.L Stock Price Chart
Explore Agios Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze 0HB0.L price movements and trends.
0HB0.L Company Profile
Discover essential business fundamentals and corporate details for Agios Pharmaceuticals, Inc. (0HB0.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
486.00
Website
https://www.agios.comCEO
Brian M. Goff
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
0HB0.L Financial Timeline
Browse a chronological timeline of Agios Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 29 Oct 2025
Upcoming earnings on 30 Jul 2025
Revenue estimate is $9.46M.
Earnings released on 1 May 2025
EPS came in at -$1.55 surpassing the estimated -$1.77 by +12.46%, while revenue for the quarter reached $8.70M, missing expectations by -7.20%.
Earnings released on 13 Feb 2025
EPS came in at -$1.69 surpassing the estimated -$1.69 by +0.12%, while revenue for the quarter reached $10.73M, beating expectations by +14.79%.
Earnings released on 31 Oct 2024
EPS came in at $16.22 surpassing the estimated $15.22 by +6.57%, while revenue for the quarter reached $8.96M, missing expectations by -5.02%.
Earnings released on 1 Aug 2024
EPS came in at -$1.69 falling short of the estimated -$1.60 by -5.65%, while revenue for the quarter reached $8.62M, missing expectations by -7.80%.
Earnings released on 2 May 2024
EPS came in at -$1.45 surpassing the estimated -$1.65 by +12.23%, while revenue for the quarter reached $8.19M, missing expectations by -2.14%.
Earnings released on 5 Mar 2024
EPS came in at -$1.72 falling short of the estimated -$1.65 by -4.16%, while revenue for the quarter reached $7.10M, missing expectations by -10.34%.
Earnings released on 2 Nov 2023
EPS came in at -$1.64 surpassing the estimated -$1.70 by +3.88%, while revenue for the quarter reached $7.40M, missing expectations by -1.69%.
Earnings released on 3 Aug 2023
EPS came in at -$1.51 surpassing the estimated -$1.56 by +3.46%, while revenue for the quarter reached $6.71M, beating expectations by +3.86%.
Earnings released on 4 May 2023
EPS came in at -$1.47 surpassing the estimated -$1.70 by +13.82%, while revenue for the quarter reached $5.61M, beating expectations by +6.98%.
Earnings released on 23 Feb 2023
EPS came in at $0.66 surpassing the estimated -$1.37 by +148.51%, while revenue for the quarter reached $4.31M, missing expectations by -4.97%.
Earnings released on 30 Sept 2022
EPS came in at -$1.49 surpassing the estimated -$1.76 by +15.52%, while revenue for the quarter reached $3.52M, missing expectations by -33.26%.
Earnings released on 30 Jun 2022
EPS came in at -$1.68 surpassing the estimated -$1.75 by +4.09%, while revenue for the quarter reached $5.58M, beating expectations by +92.12%.
Earnings released on 31 Mar 2022
EPS came in at -$1.74 surpassing the estimated -$1.74 by +0.16%, while revenue for the quarter reached $832.00K, missing expectations by -69.32%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$1.74, while revenue for the quarter reached $367.35M.
Earnings released on 30 Sept 2021
EPS came in at -$1.55 surpassing the estimated -$1.66 by +7.17%.
Earnings released on 30 Jun 2021
EPS came in at -$1.37.
Earnings released on 31 Mar 2021
EPS came in at -$1.70.
Earnings released on 31 Dec 2020
EPS came in at -$1.22, while revenue for the quarter reached $322.78M.
Earnings released on 30 Sept 2020
EPS came in at -$1.15.
0HB0.L Stock Performance
Access detailed 0HB0.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.